Loading…
Motionpharmacy.com was warned for unlawfully selling unapproved and misbranded drugs over the internet, specifically opioids, benzodiazepines, and Schedule II stimulants, in violation of the Federal Food, Drug, and Cosmetic Act sections 301(a), 301(d), 301(k), 503(b), and 505(a). The company introduced these controlled substances into interstate commerce without FDA approval and without proper labeling, creating significant public health risks given the ongoing opioid epidemic and the dangers of benzodiazepine and stimulant abuse, particularly when co-used with other substances. The violations were identified during FDA's review of the company's website operations.